Bajaj Healthcare Credit Rating

Bajaj Healthcare Earnings Call Transcript: Key Takeaways

Bajaj Healthcare delivered strong H1 growth led by a 82% surge in formulations and key new specialty launches.

Call

Guides 15% growth

Bajaj Healthcare Results Update

Bajaj Healthcare reported Q2 FY27 revenue of ₹175.9 Crore, up 18.9% YoY. EBITDA stood at ₹32.1 Crore, reflecting a 12.2% YoY increase.

Bajaj Healthcare Other Announcement

Bajaj Healthcare filed its Monitoring Agency Report for the quarter ended September 30, 2026, as required by SEBI regulations for the utilization of preferential issue proceeds.

Bajaj Healthcare Q2 FY27 Results: Net Profit ₹14.1 Cr, Up 27.0% YoY

Bajaj Healthcare Ltd reported revenue from operations of ₹175.9 Cr (+18.9% YoY) and net profit of ₹14.1 Cr (+27.0% YoY) for Q2 FY27.

Key figure

Net profit ₹14.1 Cr · +27.0% YoY

Bajaj Healthcare Acquisition

Bajaj Healthcare received NCLT approval to acquire Genrx Pharmaceuticals Private Limited as a going concern. The entity will become a wholly owned subsidiary.

Bajaj Healthcare Merger & Restructuring Worth ₹14.67 Cr

Bajaj Healthcare Limited has executed a deed of assignment to sell its undertaking located in Dahej Industrial Area, Gujarat, for approximately Rs. 14.67 Crore.

Value

₹14.67 Cr

Reliance Industries Credit Rating

Reliance Industries disclosed that S&P Global Ratings reaffirmed its 'A-' rating with a Stable outlook on its US$ senior unsecured fixed rate notes. The rating action was published on November 3, 2026.

Mahindra & Mahindra Credit Rating

CARE Ratings reaffirmed Mahindra & Mahindra's bank facility ratings at CARE AAA; Stable / CARE A1+. The action covers existing facilities and raises no new debt.

Religare Enterprises Credit Rating

Religare Enterprises disclosed that CRISIL upgraded credit ratings for its subsidiary Religare Broking's Rs. 500 Crore bank facilities. Long-term rating moved to BBB+/Stable and short-term to A2+.

UCO Bank Credit Rating

UCO Bank disclosed S&P Global Ratings assigning it a BBB long-term and A-2 short-term issuer rating, with a stable outlook. The rating rationale dated November 4, 2026 is enclosed.

Chaman Lal Setia Exports Credit Rating

Chaman Lal Setia Exports Ltd disclosed that CRISIL reaffirmed its CRISIL A+/Stable long-term rating on Rs. 350 Crore of bank loan facilities. The reaffirmation confirms unchanged credit quality, with no rating upgrade or downgrade.

Purple United Sales Credit Rating

Purple United Sales' credit rating from Crisil was reaffirmed at BBB-/Stable on Rs.175 Crore of bank facilities. The rated facilities were enhanced from Rs.100 Crore.